Drugs to suppress cough

Bibliography

• FOLKMAN J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. (1995) 1(1):27–31.
   PubMed Web of Science ®Google Scholar
• ••Excellent review of angiogenesis and itsrole in multiple disease states.
   Google Scholar
• NAGASHIMA M, ASANO G, YOSHINO S: Imbalance in production between vascular endothelial growth factor and endostatin in patients with rheumatoid arthritis. J. Rheumatol. (2000) 27(10):2339–2342.
   PubMed Web of Science ®Google Scholar
• FOX RI, KANG H: Structure and function of synoviocytes: In: Arthritis and Allied Conditions (Volume I). D McCarty, W Koopman (Eds), Lea & Febiger, Philadelphia, PA, USA (1993):263–278.
   Google Scholar
• PALEOLOG EM, MIOTLA JM: Angiogenesis in arthritis: role in disease pathogenesis and as a potential therapeutic target. Angiogenesis (1998) 2(4):295–307.
   PubMedGoogle Scholar
• COLVILLE-NASH PR, SCOTT DL: Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann. Rheum. Dis. (1992) 51(7):919–925.
   PubMed Web of Science ®Google Scholar
• WALSH DA: Angiogenesis and arthritis. Rheumatology (1999) 38(2):103–112.
   PubMed Web of Science ®Google Scholar
• STEVENS CR, BLAKE DR, MERRY P, REVELL PA, LEVICK JR: A comparative study by morphometry of the microvasculature in normal and rheumatoid synovium. Arthritis Rheum. (1991) 34(12):1508–1513.
   PubMed Web of Science ®Google Scholar
• ARSENAULT AL, LHOTAK S, HUNTER WL, BANQUERIGO ML, BRAHN E: Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularisation. Clin. Immunol. Immunopathol. (1998) 86(3):280–289.
   PubMedGoogle Scholar
• TAYLOR PC: VEGF and imaging of vessels in rheumatoid arthritis. Arthritis Res (2002) 4\(Suppl. 3):599–5107.
   Google Scholar
• ROONEY M, CONDELL D, QUINLAN Wet al.: Analysis of the histologic variation of synovitis in rheumatoid arthritis. Arthritis Rheum. (1988) 31(8):956–963.
   Google Scholar
• FRIESEL RE, MacIAG T: Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction. FASEB J. (1995) 9(10):919–925.
   PubMed Web of Science ®Google Scholar
• NABEL EG, YANG ZY, PLAUTZ G et al.: Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (1993) 362(6423):844–846.
   PubMed Web of Science ®Google Scholar
• COLLIN-OSDOBY P, ROTHE L, BEKKER S, ANDERSON F, HUANG Y, OSDOBY P: Basic fibroblast growth factor stimulates osteoclast recruitment, development, and bone pit resorption in association with angiogenesis in vivo on the chick chorioallantoic membrane and activates isolated avian osteoclast resorption in vitro. J. Bone Miner. Res. (2002) 17(10):1859–1871.
   PubMed Web of Science ®Google Scholar
• COZZOLINO F, TORCIA M, LUCIBELLO M et al.: Interferon-a and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth. J. Clin. Invest. (1993) 91(6):2504–2512.
   PubMed Web of Science ®Google Scholar
• VOLIN MV, HARLOW LA, WOODS JM et al.: Treatment with sulfasalazine or sulfapyridine, but not 5-aminosalicyclic acid, inhibits basic fibroblast growth factor-induced endothelial cell chemotaxis. Arthritis Rheum. (1999) 42(9):1927–1935.
   PubMed Web of Science ®Google Scholar
• YAIVIASHITA A, YONEMITSU Y, OKANO S et al.: Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats.. (2002) 168(1):450–457.
   Google Scholar
• DVORAK HF, BROWN LF, DETMAR M, DVORAK AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. (1995) 146(5):1029–1039.
   PubMed Web of Science ®Google Scholar
• FERRARA N, GERBER HP, J: The biology of VEGF and its receptors. Nat. Med. (2003) 9(6):669–676.
   PubMed Web of Science ®Google Scholar
• VEIKKOLA T, ALITALO K: VEGFs, receptors and angiogenesis. Semin. Cancer Biol. (1999) 9(3):211–220.
   PubMed Web of Science ®Google Scholar
• SHIBUYA M: VEGF-receptor inhibitors for anti-angiogenesis. Nippon Yakurigaku Zasshi (2003) 122(6):498–503.
   PubMedGoogle Scholar
• FAVA RA, OLSEN NJ,-GREEN G et al.: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J. Exp. Med. (1994) 180(1):341–346.
   Google Scholar
• NAGASHIMA M, YOSHINO S, ISHIWATA T, ASANO G: Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J. Rheumatol. (1995) 22(9):1624–1630.
   PubMed Web of Science ®Google Scholar
• IKEDA M, HOSODA Y, HIROSE S, OKADA Y, IKEDA E: Expression of vascular endothelial growth factor isoforms and their receptors Flt-1, KDR, and neuropilin-1 in synovial tissues of rheumatoid arthritis. J. Pathol. (2000) 191(4):426–433.
   PubMed Web of Science ®Google Scholar
• BOTTOMLEY MJ, WEBB NJ, WATSON CJ, HOLT PJ, FREEMONTAJ, BRENCHLEY PE: Peripheral blood mononuclear cells from patients with rheumatoid arthritis spontaneously secrete vascular endothelial growth factor (VEGF): specific up-regulation by tumour necrosis factor-a (TNF-a) in synovial fluid. Clin. Exp. Immunol. (1999) 117(1):171–176.
   PubMed Web of Science ®Google Scholar
• FEARON U, GRIOSIOS K, FRASER A et al.: Angiopoietins, growth factors, and vascular morphology in early arthritis. Rheumatol. (2003) 30(2):260–268.
   Web of Science ®Google Scholar
• SMEETS TJ, BARG EC, KRAAN MC, SMITH MD, BREED VELD FC, TAK PP: Analysis of the cell infiltrate and expression of proinflammatory cytokines and matrix metalloproteinases in arthroscopic synovial biopsies: comparison with synovial samples from patients with end stage, destructive rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(7):635–638.
   PubMed Web of Science ®Google Scholar
• KOCH AE, HARLOW LA, HAINES GK et al.: Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J. Immunol. (1994) 152(8):4149–4156.
   Google Scholar
• GIATROMANOLAKI A. SIVRIDIS E, ATHANASSOU N et at.: The angiogenic 'vascular endothelial growth factor/ flk-1(KDR)-receptor' in rheumatoid arthritis and osteoarthritis. j Pathol. (2001) 194(1):101–108.
   Google Scholar
• SEKIMOTO T, HAMADA K, OIKE Y et al.: Effect of direct angiogenesis in rheumatoid arthritis using a soluble vascular endothelial growth factor receptor 1 chimeric protein. J. Rheumatol (2002) 29(2):240–245.
   PubMed Web of Science ®Google Scholar
• MOULD AW, TONKS ID, CAHILL MM et al.: Vegfb gene knockout mice display reduced pathology and synovial angiogenesis in both antigen-induced and collagen-induced models of arthritis. Arthritis Rheum. (2003) 48(9):2660–2669.
   PubMed Web of Science ®Google Scholar
• LATOUR F, ZABRANIECKI L, DROMER C, BROUCHET A, DURROUX R, FOURNIE B: Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological, and pathological study in 12 patients monitored for 10 years. Joint Bone Spine (2001) 68(6):493–498.
   PubMed Web of Science ®Google Scholar
• MIOTLA J, MacIEWICZ R, J, FELDMANN M, PALEOLOG E: Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab. Invest. (2000) 80(8):1195–1205.
   PubMed Web of Science ®Google Scholar
• SONE H, KAWAKAMI Y, SAKAUCHI M et al.: Neutralization of vascular endothelial growth factor prevents collagen-induced arthritis and ameliorates established disease in mice. Biochem. Biophys. Res. Commun. (2001) 281(2):562–568.
   PubMed Web of Science ®Google Scholar
• BERSE B, HUNT JA, DIEGEL RJ et al.: Hypoxia augments cytokine (transforming growth factor-I3 (TGF-13) and IL-1)-induced vascular endothelial growth factor secretion by human synovial fibroblasts. Clin. Exp. Immunol (1999) 115(1):176–182.
   PubMed Web of Science ®Google Scholar
• SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (1992) 359(6398):843–845.
   PubMed Web of Science ®Google Scholar
• LEVY NS, CHUNG S, FURNEAUX H, LEVY AP: Hypoxic stabilization of vascular endothelial growth factor mRNA by the RNA-binding protein HuR. J. Biol. Chem. (1998) 273(11):6417–6423.
   PubMed Web of Science ®Google Scholar
• GIATROMANOLAKI A, SIVRIDIS E, MALTEZOS E et al.: Upregulated hypoxia inducible factor-la and -2a pathway in arthritis and osteoarthritis. Arthritis Res Ther (2003) 5(4):R193–R201.
   PubMed Web of Science ®Google Scholar
• PALEOLOG EM, YOUNG S, STARK AC, MCCLOSKEY RV, FELDMANN M, MAINI RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor a and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. (1998) 41(7):1258–1265.
   PubMed Web of Science ®Google Scholar
• KLIMIUK PA, SIERAKOWSKI S, FIEDORCZYK M, CHWIECKO J: [Serum tumor necrosis factor a (TNF-a) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis]. Przegl. Lek. (2004) 61(2):86–89.
   PubMedGoogle Scholar
• CANETE JD, PABLOS JL, SANMARTI R et al.: Antiangiogenic effects of anti-tumor necrosis factor a therapy with infliximab in psoriatic arthritis. Arthritis Rheum. (2004) 50(5):1636–1641.
   PubMed Web of Science ®Google Scholar
• WILDER RL: Integrin avI33 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann. Rheum. Dis. (2002) 61\(Suppl. 2):ii96-ii99.
   Google Scholar
• •Comprehensive review of integrin avI33 and its role in treating rheumatologic disorders.
   Google Scholar
• ELICEIRI BP, CHERESH DA: The role of av integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. (1999) 103(9):1227–1230.
   PubMed Web of Science ®Google Scholar
• KUMAR CC: Integrin a,J33 as a therapeutic target for blocking tumor-induced angiogenesis. Curr. Drug Targets (2003) 4(2):123–131.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, CLARK RA, DA: Requirement of vascular avI33 for angiogenesis. Science (1994) 264(5158):569–571.
   PubMed Web of Science ®Google Scholar
• JOHNSON BA, HAINES GK, HARLOW LA, KOCH AE: Adhesion molecule expression in human synovial tissue. Arthritis Rheum. (1993) 36(2):137–146.
   PubMed Web of Science ®Google Scholar
• SURI C, JONES PF, PATAN S et al.: Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell (1996) 87(7): 1171–1180.
   PubMed Web of Science ®Google Scholar
• DAVIS S, ALDRICH TH, JONES PF et al.: Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell (1996) 87(7):1161–1169.
   PubMed Web of Science ®Google Scholar
• MAISONPIERRE PC, SURI C, PF et al.: Angiopoietin-2, a natural for Tie2 that disrupts in vivo angiogenesis. Science (1997) 277(5322):55–60.
   PubMed Web of Science ®Google Scholar
• UCHIDA T, NAKASHIMA M, HIROTAY, MIYAZAKI Y, T, SHINDO H: Immunohistochemical localisation of protein tyrosine kinase receptors Tie-1 and Tie-2 in synovial tissue of rheumatoid arthritis: correlation with angiogenesis and synovial proliferation. Ann. Rheum. Dis. (2000) 59(8):607–614.
   PubMed Web of Science ®Google Scholar
• DEBUSK LM, CHEN Y, NISHISHITA T, CHEN J, THOMAS JW, LIN PC: Tie2 receptor tyrosine kinase, a major mediator of tumor necrosis factor a-induced angiogenesis in rheumatoid arthritis. Arthritis Rheum. (2003) 48(9):2461–2471.
   PubMed Web of Science ®Google Scholar
• GRAVALLESE EM, PETTIT AR, LEE R et al.: Angiopoietin-1 is expressed in the synovium of patients with rheumatoid arthritis and is induced by tumour necrosis factor a. Ann. Rheum. Dis. (2003) 62(2):100–107.
   PubMed Web of Science ®Google Scholar
• SHAHRARA S, VOLIN MV CONNORS MA, HAINES GK, AE: Differential expression of the angiogenic Tie receptor family in arthritic and normal synovial tissue. Arthritis Res. (2002) 4(3):201–208.
   PubMedGoogle Scholar
• SCOTT BB, ZARATIN PF, A, HANSBURY MJ, WINKLER JD, JACKSON JR: Constitutive expression of angiopoietin-1 and -2 and modulation of their expression by inflammatory cytokines in rheumatoid arthritis synovial fibroblasts. J. Rheumatol (2002) 29(2):230–239.
   PubMed Web of Science ®Google Scholar
• TAKAHARA K, IIOKA T, FURUKAWA K et al.: Autocrine/paracrine role of the angiopoietin-1 and -2/Tie2 system in cell proliferation and chemotaxis of cultured fibroblastic synoviocytes in rheumatoid arthritis. Hum. Pathol (2004) 35(2):150–158.
   PubMed Web of Science ®Google Scholar
• SEMENZA GL: Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer (2003) 3(10):721–732.
   PubMed Web of Science ®Google Scholar
• JIANG BH, RUE E, WANG GL, ROE R, SEMENZA GL: Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1.1 Biol. Chem. (1996) 271(30):17771–17778.
   Google Scholar
• DISTLER K: [Hypoxia and angiogenesis in rheumatic diseases]. Z. Rheumatol. (2003) 62\(Suppl. 2):I143–1145.
   Google Scholar
• LIU LX, LU H, LUO Yet al.: Stabilization of vascular endothelial growth factor mRNA by hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. (2002) 291(4):908–914.
   Google Scholar
• HARA S, KOBAYASHI C, IMURA N: Nuclear localization of hypoxia-inducible factor-2a in bovine arterial endothelial cells. Mol. Cell. Biol. Res. Commun. (1999) 2(2):119–123.
   PubMedGoogle Scholar
• HOLLANDER AP CORKE KP, FREEMONT AJ, LEWIS CE: Expression of hypoxia-inducible factor la by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. (2001) 44(7):1540–1544.
   PubMed Web of Science ®Google Scholar
• JACKSON JR, MINTON JA, HO ML, WET N, WINKLER JD: Expression of vascular endothelial growth factor in synovial fibroblasts is induced by hypoxia and interleukin 113.1 Rheumatol (1997) 24(7):1253–1259.
   Google Scholar
• PETERS CL, MORRIS CJ, MAPP PI, BLAKE DR, LEWIS CE, WINROW VR: The transcription factors hypoxia-inducible factor la and Ets-1 colocalize in the hypoxic synovium of inflamed joints in adjuvant-induced arthritis. Arthritis Rheum. (2004) 50(1):291–296.
   PubMed Web of Science ®Google Scholar
• YEO EJ, CHUN YS, CHO YS et al: YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1.1 Nail. Cancer Inst. (2003) 95(7):516–525.
   Google Scholar
• YEO EJ, CHUN YS, PARK JW: New anticancer strategies targeting HIF-1. Biochem. Pharmacol (2004) 68(6):1061–1069.
   PubMed Web of Science ®Google Scholar
• MARTEL-PELLETIER J, PELLETIER JP, FAHMI H: Cyclooxygenase-2 and prostaglandins in articular tissues. Semin. Arthritis Rheum. (2003) 33(3):155–167.
   PubMed Web of Science ®Google Scholar
• ZICHE M, JONES J, GULLINO PM: Role of prostaglandin El and copper in angiogenesis. J. Natl. Cancer Inst. (1982) 69(2):475–482.
   PubMed Web of Science ®Google Scholar
• FORM DM, AUERBACH R: PGE, and angiogenesis. Proc. Soc. Exp. Bid. Med. (1983) 172(2):214–218.
   PubMed Web of Science ®Google Scholar
• JONES MK, WANG H, PESKAR BM et al.: Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. (1999) 5(12):1418–1423.
   PubMed Web of Science ®Google Scholar
• MAJIMA M, ISONO M, IKEDA Y et ell.: Significant roles of inducible cyclooxygenase (COX)-2 in angiogenesis in rat sponge implants. Jpn. j Pharmacol (1997) 75(2):105–114.
   Google Scholar
• TSUJII M, KAWANO S, TSUJI S, SAWAOKA H, HORI M, DUBOIS RN: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell (1998) 93(5):705–716.
   PubMed Web of Science ®Google Scholar
• DORMOND O, FOLETTI A, PAROZ C, RUEGG C: NSAIDs inhibit a,133 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis. Nat. Med. (2001) 7(9):1041–1047.
   PubMed Web of Science ®Google Scholar
• DORMOND O, BEZZI M, A. RUEGG C: Prostaglandin E2 promotes integrin avf33-dependent endothelial cell adhesion, rac-activation, and spreading through cAMP/PKA-dependent signaling. 1 Biol. Chem. (2002) 277(48):45838–45846.
   Google Scholar
• BEN AV P, CROFFORD LJ, WILDER RL, HLA T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett. (1995) 372(1):83–87.
   PubMed Web of Science ®Google Scholar
• WOODS JM, MOGOLLON A. MA, MARTINEZ RJ, KOCH AE: The role of COX-2 in angiogenesis and rheumatoid arthritis. Exp. MoL Pathol (2003) 74(3):282–290.
   PubMed Web of Science ®Google Scholar
• KATORI M, MAJIMA M, HARADA Y: Possible background mechanisms of the effectiveness of cyclooxygenase-2 inhibitors in the treatment of rheumatoid arthritis. Inflamm. Res. (1998) 47\(Suppl. 2):5107–S111.
   Google Scholar
• KONTTINEN YT, AINOLA M, VALLEALA H et al.: Analysis of 16 different matrix metalloproteinases (MMP-1 to MMP-20) in the synovial membrane: different profiles in trauma and rheumatoid arthritis. Ann. Rheum. Dis. (1999) 58(11):691–697.
   PubMed Web of Science ®Google Scholar
• NAGASE H, BREW K: Designing TIMP (tissue inhibitor of metalloproteinases) variants that are selective metalloproteinase inhibitors. Biochem. Soc. Symp. (2003) (70):201–212.
   Google Scholar
• JACKSON C: Matrix metalloproteinases and angiogenesis. Curr. Opin. Nephrol. Hypertens. (2002) 11(3):295–299.
   PubMed Web of Science ®Google Scholar
• MOSES Mk The regulation of neovascularization of matrix and their inhibitors. Stem Cells (1997) 15(3):180–189.
   PubMed Web of Science ®Google Scholar
• JACKSON CJ, ARKELL J, NGUYEN M: Rheumatoid synovial endothelial cells secrete decreased levels of tissue inhibitor of MMP (TIMP1). Ann. Rheum. Dis. (1998) 57(3):158–161.
   PubMed Web of Science ®Google Scholar
• KOLB C, MAUCH S, KRAWINKEL U, SEDLACEK R: Matrix metalloproteinase-19 in capillary endothelial cells: expression in acutely, but not in chronically, inflamed synovium. Exp. Cell Res. (1999) 250(1):122–130.
   PubMed Web of Science ®Google Scholar
• FRASER A, FEARON U, REECE R, EMERY P, VEALE DJ: Matrix metalloproteinase 9, apoptosis, and vascular morphology in early arthritis. Arthritis Rheum. (2001) 44(9):2024–2028.
   PubMed Web of Science ®Google Scholar
• CHAKRABORTI S, MANDAL M, DAS S, MANDAL A, CHAKRABORTI T: Regulation of matrix metalloproteinases: an overview. MoL Cell. Biochem. (2003) 253(1-2):269–285.
   PubMed Web of Science ®Google Scholar
• PARK CC, MOREL JC, AMIN MA, CONNORS MA, HARLOW LA, KOCH AE: Evidence of IL-18 as a novel angiogenic mediator./ Immunol. (2001) 167(3):1644–1653.
   PubMed Web of Science ®Google Scholar
• STRIETER RM, POLVERINI PJ, KUNKEL SL et al: The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. (1995) 270(45):27348–27357.
   PubMed Web of Science ®Google Scholar
• VOLIN MV, WOODS JM, AMIN MA, CONNORS MA, HARLOW LA, AE: Fractalkine: a novel angiogenic chemokine in rheumatoid arthritis. Am. J. Pathol (2001) 159(4):1521–1530.
   PubMed Web of Science ®Google Scholar
• KOCH AE: Angiogenesis as a target in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62\(Suppl. 2):ii60-ii67.
   Google Scholar
• •Excellent review of the modulators involved in the angiogenesis of arthritis.
   Google Scholar
• O'REILLY MS, HOLMGREN L, SHING Y et al: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79(2):315–328.
   PubMed Web of Science ®Google Scholar
• ••First report of any naturally ocurringangiogenesis inhibitor.
   Google Scholar
• CAO Y, CAO R, VEITONMAKI N: Kringle structures and antiangiogenesis. Curr. Med. Chem. Anti-Canc. Agents (2002) 2(6):667–681.
   PubMedGoogle Scholar
• KIM JM, HO SH, PARK EJ et al: Angiostatin gene transfer as an effective treatment strategy in murine collagen- arthritis. Arthritis Rheum. (2002) 46 (3) :793–801.
   PubMed Web of Science ®Google Scholar
• KATO K, MIYAKE K, IGARASHI T, YOSHINO S, SHIMADA T: Human immunodeficiency virus vector-mediated intra-articular expression of angiostatin inhibits progression of collagen-induced arthritis in mice. Rheumatol Int. (2004) (In Press).
   Google Scholar
• SUMARIWALLA PF, GAO Y, WU HL, FELDMANN M, PALEOLOG EM: The angiogenesis inhibitor protease-activated kringles 1-5 reduces the severity of murine collagen-induced arthritis. Arthritis Res. Ther. (2003) 5(1):R32–R39.
   PubMed Web of Science ®Google Scholar
• O'REILLY MS, BOEHM T, SHING Y et al.: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell (1997) 88(2):277–285.
   Google Scholar
• •First report of endostatin as an inhibitor of angiogenesis.
   Google Scholar
• DIXELIUS J, CROSS MJ, MATSUMOTO T,-WELSH L: Endostatin action and intracellular signaling: 13-catenin as a potential target? Cancer Lett. (2003) 196(1):1–12.
   Google Scholar
• MATSUNO H, YUDOH K, UZUKI M et al.: Treatment with the angiogenesis inhibitor endostatin: a novel therapy in rheumatoid arthritis./ Rheumatol (2002) 29(5):890–895.
   PubMed Web of Science ®Google Scholar
• YIN G, LIU W, AN P et al.: Endostatin gene transfer inhibits joint angiogenesis and pannus formation in inflammatory arthritis. Mo/. Ther. (2002) 5(5 Pt 0:547–554.
   Google Scholar
• KUROSAKA D, YOSHIDA K, YASUDA J et al.: Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann. Rheum. Dis. (2003) 62(7):677–679.
   PubMed Web of Science ®Google Scholar
• YUE L, WANG H, LIU LH, SHEN YX, WEI W: Anti-adjuvant arthritis of recombinant human endostatin in rats via inhibition of angiogenesis and proinflammatory factors. Acta Pharmacol Sin. (2004) 25(9):1182–1185.
   PubMed Web of Science ®Google Scholar
• CHILLEMI F, FRANCESCATO P, RAGG E, CATTANEO MG, POLA S, VICENTINI L: Studies on the structure-activity relationship of endostatin: synthesis of human endostatin peptides exhibiting potent antiangiogenic activities. J. Med. Chem. (2003) 46(19):4165–4172.
   PubMed Web of Science ®Google Scholar
• JIMENEZ B, VOLPERT OV, CRAWFORD SE, FEBBRAIO M, SILVERSTEIN RL, BOUCK N: Signals to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat. Med. (2000) 6(1):41–48.
   PubMed Web of Science ®Google Scholar
• KOCH AE, SZEKANECZ Z, J, HAINES GK, CB, BOUCK NP: Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis. Clin. Immunol Immunopathol (1998) 86(2):199–208.
   PubMedGoogle Scholar
• WU H, BEUERLEIN G, NIE Y et al.: Stepwise in vitro affinity maturation of Vitaxin, an avflo-specific humanized mAb. Proc. Natl Acad. Sci. USA (1998) 95(11):6037–6042.
   PubMed Web of Science ®Google Scholar
• VAN DER ZR, MUROHARA T, J, KEARNEY M, DA, ISNER JM: Reduced intimal thickening following a(v)133 blockade is associated with smooth muscle cell apoptosis. Cell Adhes. Commun. (1998) 6(5):371–379.
   PubMedGoogle Scholar
• NIP J, SHIBATA H, LOSKUTOFF DJ, CHERESH DA, BRODT P: Human melanoma cells derived from lymphatic metastases use integrin avflo to adhere to lymph node vitronectin. j Clin. Invest. (1992) 90(4):1406–1413.
   PubMed Web of Science ®Google Scholar
• BROOKS PC, MONTGOMERY AM, ROSENFELD M et al.: Integrin avflo antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell (1994) 79(7):1157–1164.
   PubMed Web of Science ®Google Scholar
• DRAKE CJ, CHERESH DA, CD: An antagonist of integrin avflo prevents maturation of blood vessels during embryonic neovascularization. J. Cell Sci. (1995) 108 (Pt 7):2655–2661.
   PubMedGoogle Scholar
• BROOKS PC, STROMBLAD S, KLEMKE R, VISSCHER D, SARKAR FH, CHERESH DA: Antiintegrin avflo blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. (1995) 96(4):1815–1822.
   PubMed Web of Science ®Google Scholar
• GUTHEIL JC, CAMPBELL TN, PIERCE PR et al.: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin avflo. Clin. Cancer Res. (2000) 6(8):3056–3061.
   PubMed Web of Science ®Google Scholar
• STORGARD CM, STUPACK DG, JONCZYK A, GOODMAN SL, FOX RI, CHERESH DA: Decreased angiogenesis and arthritic disease in rabbits treated with an av133 antagonist. J. Clin. Invest. (1999) 103(1):47–54.
   PubMed Web of Science ®Google Scholar
• BADGER AM, BLAKE S, KAPADIA R et al.: Disease-modifying activity of SB 273005, an orally active, nonpeptide avflo (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis. Arthritis Rheum. (2001) 44(1):128–137.
   PubMed Web of Science ®Google Scholar
• COLEMAN KR, BRADEN GA, WILLINGHAM MC, SANE DC: Vitaxin, a humanized monoclonal antibody to the vitronectin receptor (avf33), reduces neointimal hyperplasia and total vessel area after balloon injury in hypercholesterolemic rabbits. Circ. Res. (1999) 84(10:1268–1276.
   PubMedGoogle Scholar
• HYNES RO: A reevaluation of integrins as regulators of angiogenesis. Nat. Med. (2002) 8(9):918–921.
   PubMed Web of Science ®Google Scholar
• ADAMS JD, FLORA KP, BR, WILSON JW, ARBUCK SG, FINLEY R: Taxol: a history of pharmaceutical development and current pharmaceutical concerns. J. Natl. Cancer Inst. Monogr (1993)(15):141–147.
   Google Scholar
• OLIVER SJ, BANQUERIGO ML, BRAHN E: Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell. Immunol (1994) 157(1):291–299.
   PubMed Web of Science ®Google Scholar
• BRAHN E, TANG C, ML: Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum. (1994) 37(0:839–845.
   PubMedGoogle Scholar
• HUI k KULKARNI GV, HUNTER WL, MCCULLOCH CA, CRUZ TF: Paclitaxel selectively induces mitotic arrest and apoptosis in proliferating bovine synoviocytes. Arthritis Rheum. (1997) 40(6):1073–1084.
   PubMed Web of Science ®Google Scholar
• KUROSE A, YOSHIDA W, YOSHIDA M, SAWAI T: Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis. Cytometry (2001) 44(4):349–354.
   PubMedGoogle Scholar
• Y00 WH, BAEK HS: Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma. J. Rheumatol (2000) 27(6):1572–1573.
   Web of Science ®Google Scholar
• SCHELLER B, SPECK U, ABRAMJUK C, BERNHARDT U, BOHM M, NICKENIG G: Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation (2004) 110(7):810–814.
   PubMed Web of Science ®Google Scholar
• VOGT F, STEIN k RETTEMEIER G et al.: Long-term assessment of a novel biodegradable paclitaxel-eluting coronary 111. stent. Eur. Heart J. (2004) 25(15):1330–1340.
   Google Scholar
• GERSHLICK A, DE SCHEERDER I et al.: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent: the European evaLUation of pacliTaxel Eluting Stent (ELUTES) trial. Circulation (2004) 109(4):487–493.
   Google Scholar
• HONG MK, MINTZ GS, LEE CW et al: Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries: a serial volumetric intravascular ultrasound analysis from the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation (2003) 107(4):517–520.
   PubMed Web of Science ®Google Scholar
• STONE GW, ELLIS SG, COX DA et al: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 109(16):1942–1947.
   PubMed Web of Science ®Google Scholar
• STONE GW, ELLIS SG, COX DA et al: A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl. J. Med. (2004) 350(3):221–231.
   PubMed Web of Science ®Google Scholar
• INGBER D, FUJITA T, KISHIMOTO S et al: Synthetic analogues of fitmagillin that inhibit angiogenesis and suppress tumour growth. Nature (1990) 348(6301):555–557.
   PubMed Web of Science ®Google Scholar
• •Report on the discovery and synthesis of fumagillin derivatives as angiogenesis inhibitors.
   Google Scholar
• GRIFFITH EC, SU Z, TURK BE et al: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem. Biol. (1997) 4(6):461–471.
   PubMed Web of Science ®Google Scholar
• PEACOCK DJ, BANQUERIGO ML, BRAHN E: Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. (1992) 175(4):1135–1138.
   PubMed Web of Science ®Google Scholar
• ••First report of an angiogenesis inhibitorused in rheumatologic disease.
   Google Scholar
• PEACOCK DJ, BANQUERIGO ML, BRAHN E: A novel angiogenesis inhibitor suppresses rat adjuvant arthritis. Cell. Immunol (1995) 160(2):178–184.
   PubMed Web of Science ®Google Scholar
• OLIVER SJ, CHENG TP, BANQUERIGO ML, BRAHN E: Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cell. Immunol (1995) 166(2):196–206.
   PubMed Web of Science ®Google Scholar
• DE BANDT M, GROSSIN M, AJ et al.: Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a mouse model of rheumatoid arthritis. Arthritis Rheum. (2000) 43(9):2056–2063.
   PubMed Web of Science ®Google Scholar
• NAGASHIMA M, TANAKA H, TAKAHASHI H et al.: Study of the mechanism involved in angiogenesis and synovial cell proliferation in human synovial tissues of patients with rheumatoid arthritis using SCID mice. Lab. Invest. (2002) 82(8):981–988.
   PubMed Web of Science ®Google Scholar
• SATCHI-FAINARO R, PUDER M, DAVIES jw et al.: Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. (2004) 10(3):255–261.
   PubMed Web of Science ®Google Scholar
• BERNIER SG, LAZARUS DD, CLARK E et al.: A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc. Natl Acad. Sci. USA (2004) 101(29):10768–10773.
   PubMed Web of Science ®Google Scholar
• BRAHN E, BANQUERIGO ML, SCHOETTLER NR, LEE S: A new angiogenesis inhibitor, PPI-2458: regression of collagen-induced arthritis and prevention of erosions. Arthritis Rheum. (2001) 44:S271.
   Web of Science ®Google Scholar
• BRAHN E, SCHOETTLER NR, BANQUERIGO ML, THOMPSON CD: Involution of collagen-induced arthritis with an angiogenesis inhibitor PPI-2458. Arthritis Rheum. (2003) 48:S347.
   Web of Science ®Google Scholar
• WOOD JM, BOLD G, E et al.: PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res. (2000) 60(8):2178–2189.
   PubMed Web of Science ®Google Scholar
• DREVS J, HOFMANN I, H et al.: Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Res. (2000) 60(17):4819–4824.
   PubMed Web of Science ®Google Scholar
• GROSIOS K, WOOD J, ESSER R, RAYCHAUDHURI A, DAWSON J: Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflamm. Res. (2004) 53(4):133–142.
   PubMed Web of Science ®Google Scholar
• SOLORZANO CC, BAKER CH, BRUNS CJ et al: Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biother. Radiopharm. (2001) 16(5):359–370.
   PubMed Web of Science ®Google Scholar
• LIN B, PODAR K, GUPTA D et al: The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. (2002) 62(17):5019–5026.
   PubMed Web of Science ®Google Scholar
• SCHOENBERGER J, GRIMM D, KOSSMEHL P, INFANGER M, E, EILLES C: Effects of PTK787/ ZK222584, a tyrosine kinase inhibitor, on the growth of a poorly differentiated thyroid carcinoma: an animal study. Endocrinology (2004) 145(3):1031–1038.
   PubMed Web of Science ®Google Scholar
• KLEM J: Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer. Clin. Colorectal Cancer (2003) 3(3):147–149.
   PubMedGoogle Scholar
• GOLDBRUNNER RH, BENDSZUS M, WOOD J, KIDERLEN M, SASAKI M, TONN JC: PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery (2004) 55(2):426–432.
   PubMed Web of Science ®Google Scholar
• HARTMAN GD, FRALEY ME, BILODEAU MT: Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents. Expert Opin. Investig Drugs (2002) 11(6):737–745.
   PubMed Web of Science ®Google Scholar
• ELARAJ DM, WHITE DE, SM, HAWORTH L, ROSENBERG SA, YANG JC: A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.. (2004) 27(4):259–264.
   Google Scholar
• RINI BI, HALABI S, TAYLOR J, SMALL EJ, SCHILSKY RL: Cancer and Leukemia Group B 90206: a randomized Phase III trial of interferon-a or interferon-a plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin. Cancer Res. (2004) 10(8):2584–2586.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, GRAY R, GIANTONIO B, O'DWYER P, COMIS RL: Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin. Cancer Res. (2004) 10(4):1206–1211.
   PubMed Web of Science ®Google Scholar
• YANG JC, HAWORTH L, SHERRY RM et al: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor 16, for metastatic renal cancer. Engl. J. Med. (2003) 349(5):427–434.
   PubMed Web of Science ®Google Scholar
• COBLEIGH MA, LANGMUIR VK, SLEDGE GW et al.: A Phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin. Oncol (2003) 30(5 Suppl. 16):117–124.
   Google Scholar
• MILLER KD: E2100: a Phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin. Breast Cancer (2003) 3(0:421–422.
   PubMedGoogle Scholar
• RAMASWAMY B, SHAPIRO CL: Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer. Clin. Breast Cancer (2003) 4(4):292–294.
   PubMedGoogle Scholar
• JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184–2191.
   PubMed Web of Science ®Google Scholar
• SANDLER AB, JOHNSON DH, HERBST RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin. Cancer Res. (2004) 10(12 Pt 2):4258s–4262s.
   Google Scholar
• DIAZ-RUBIO E: New chemotherapeutic advances in pancreatic, colorectal, and gastric cancers. Oncologist (2004) 9(3):282–294.
   PubMed Web of Science ®Google Scholar
• FRUCHT H, STEVENS PD, DR et al.: Advances in the Genetic Screening, Work-up, and Treatment of Pancreatic Cancer. Cuff. Treat Options Gastroenterol (2004) 7(5):343–354.
   PubMedGoogle Scholar
• FIGG WD, KRUGER EA, PRICE DK, KIM S, DAHUT WD: Inhibition of angiogenesis: treatment options for patients with metastatic prostate cancer. Invest. New Drugs (2002) 20(2):183–194.
   PubMed Web of Science ®Google Scholar
• AGUAYO A: The role of angiogenesis in the biology and therapy of myelodysplastic syndromes. Curr. HematoL Rep. (2004) 3(3):184–191.
   PubMedGoogle Scholar
• LIST AF: New approaches to the treatment of myelodysplasia. Oncologist (2002) 7\(Suppl. 1):39–49.
   Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY Wet al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl. J. Med. (2004) 350(23):2335–2342.
   Google Scholar
• ••Publication of this trial ultimately led tothe first FDA approval of an angiogenesis inhibitor in treating cancer.
   Google Scholar
• KABBINAVAR F, HURWITZ HI, FEHRENBACHER Let al.: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol (2003) 21(1):60–65.
   Google Scholar
• D'AMATO RJ, LOUGHNAN MS, FLYNN E, FOLKMAN J: Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA (1994) 91(9):4082–4085.
   PubMed Web of Science ®Google Scholar
• CORRAL LG, HASLETT PA, GW et al.: Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-a. J. Immunol (1999) 163(1):380–386.
   PubMed Web of Science ®Google Scholar
• OLIVER SJ, CHENG TP, ML, BRAHN E: The effect of thalidomide and 2 analogs on collagen induced arthritis. J. Rheumatol (1998) 25(5):964–969.
   PubMed Web of Science ®Google Scholar
• HAUSCHILD A, KROEGER H, MITCHISON NA, UGRINOVIC S, ZWINGENBERGER K: Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an Th2 shift. Clin. Exp. Immunol (1997) 108(3):428–431.
   PubMed Web of Science ®Google Scholar
• OLIVER SJ, FREEMAN SL, LG, OCAMPO CJ, KAPLAN G: Thalidomide analogue CC1069 inhibits development of rat arthritis. Clin.Immunol (1999) 118(2):315–321.
   Web of Science ®Google Scholar
• KROGER H, MIESEL R, DIETRICH A, OHDE M, RAJNAVOLGYI E, OCKENFELS H: Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on Type II collagen-induced arthritis in mice. Inflammation (1996) 20(2):203–215.
   PubMed Web of Science ®Google Scholar
• HUIZINGA TW, DIJKMANS BA, VAN DER VELDE EA, DE POUW KRAAN TC, VERWEIJ CL, BREEDVELD FC: An open study of pentoxyfylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. (1990 55(11):833–836.
   Google Scholar
• GUTIERREZ-RODRIGUEZ O: Thalidomide. A promising new treatment for rheumatoid arthritis. Arthritis Rheum. (1984) 27(10):1118–1121.
   PubMed Web of Science ®Google Scholar
• GUTIERREZ-RODRIGUEZ O, STARUSTA-BACAL P, GUTIERREZ-MONTES 0: Treatment of refractory rheumatoid arthritis-the thalidomide experience. J. Rheumatol (1989) 16(2):158–163.
   PubMed Web of Science ®Google Scholar